Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXRNASDAQ:CYCCNASDAQ:ENTONASDAQ:KPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$1.08+18.3%$0.84$0.65▼$26.25$11.48M0.87658,302 shs2.90 million shsCYCCCyclacel Pharmaceuticals$0.34+1.0%$2.42$0.25▼$39.84$7.65M0.24399,510 shs1.29 million shsENTOEntero Therapeutics$0.53+9.6%$0.42$0.19▼$1.93$2.53M0.85727,922 shs1.77 million shsKPRXKiora Pharmaceuticals$3.20+6.0%$3.11$2.51▼$4.86$9.74M-0.68134,674 shs184,699 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals0.00%+23.49%+49.17%-28.95%-92.92%CYCCCyclacel Pharmaceuticals0.00%-17.28%-76.65%-93.34%-98.58%ENTOEntero Therapeutics0.00%+8.30%+27.64%-12.38%-72.63%KPRXKiora Pharmaceuticals0.00%+5.96%+4.23%-2.74%-25.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXRCitius Pharmaceuticals1.8596 of 5 stars3.42.00.00.00.60.81.3CYCCCyclacel Pharmaceuticals0.179 of 5 stars0.03.00.00.00.01.70.0ENTOEntero TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKPRXKiora Pharmaceuticals3.0829 of 5 stars3.55.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.80Moderate Buy$54.504,946.30% UpsideCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AENTOEntero Therapeutics 0.00N/AN/AN/AKPRXKiora Pharmaceuticals 3.00Buy$10.00212.50% UpsideCurrent Analyst Ratings BreakdownLatest ENTO, CTXR, CYCC, and KPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025KPRXKiora PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/ACYCCCyclacel Pharmaceuticals$40K191.33N/AN/A($3.93) per share-0.09ENTOEntero TherapeuticsN/AN/AN/AN/A($0.82) per shareN/AKPRXKiora Pharmaceuticals$16.02M0.61$1.24 per share2.58$8.58 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$39.14MN/A0.000.86N/AN/A-58.63%-37.67%8/11/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$11.21M-$56.00N/A∞N/A-18,150.00%-3,648.09%-155.99%6/24/2025 (Estimated)ENTOEntero Therapeutics-$18.06MN/A0.00∞N/AN/A-1,063.82%-26.06%N/AKPRXKiora Pharmaceuticals$3.60M-$2.90N/AN/AN/AN/A-42.82%-32.18%8/8/2025 (Estimated)Latest ENTO, CTXR, CYCC, and KPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04N/A$0.03 millionN/A5/15/2025Q1 2025ENTOEntero TherapeuticsN/A-$0.21N/A-$0.28N/AN/A5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/9/2025Q1 2025KPRXKiora Pharmaceuticals-$0.77-$0.52+$0.25-$0.52$0.75 millionN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/25/2025Q4 2024KPRXKiora Pharmaceuticals-$0.64-$1.04-$0.40-$1.04$0.75 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ALatest ENTO, CTXR, CYCC, and KPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.370.06CYCCCyclacel PharmaceuticalsN/A5.605.60ENTOEntero TherapeuticsN/A2.902.90KPRXKiora PharmaceuticalsN/A5.145.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%CYCCCyclacel Pharmaceuticals23.58%ENTOEntero Therapeutics12.30%KPRXKiora Pharmaceuticals76.97%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals10.70%CYCCCyclacel Pharmaceuticals96.90%ENTOEntero Therapeutics0.75%KPRXKiora Pharmaceuticals0.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableCYCCCyclacel Pharmaceuticals1422.45 million696,000OptionableENTOEntero Therapeutics94.77 million4.73 millionN/AKPRXKiora Pharmaceuticals103.04 million3.04 millionNot OptionableENTO, CTXR, CYCC, and KPRX HeadlinesRecent News About These CompaniesKiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.3% - Should You Sell?June 17, 2025 | americanbankingnews.comkiora pharmaceuticals reports results of annual shareholder meetingJune 6, 2025 | investing.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | finanznachrichten.deKiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | newsfilecorp.comKiora Pharmaceuticals Reports Q1 2025 Financial ResultsMay 31, 2025 | tipranks.comKiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027May 9, 2025 | newsfilecorp.comKiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative VitreoretinopathyMay 5, 2025 | finance.yahoo.comKiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | newsfilecorp.comKiora Pharmaceuticals Advances Retinal Disease PipelineMarch 26, 2025 | tipranks.comKiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027March 25, 2025 | newsfilecorp.comKiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual MeetingMarch 12, 2025 | newsfilecorp.comKiora Pharmaceuticals secures new patent for KIO-104February 13, 2025 | msn.comKiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104February 13, 2025 | newsfilecorp.comKiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular EdemaFebruary 11, 2025 | newsfilecorp.comWe Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be ConservativeNovember 15, 2024 | finance.yahoo.comKiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial PositionNovember 13, 2024 | markets.businessinsider.comKiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 StudiesNovember 8, 2024 | newsfilecorp.comPositive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy RatingNovember 1, 2024 | markets.businessinsider.comKiora Pharmaceuticals Gains Approval for Phase 2 TrialOctober 29, 2024 | markets.businessinsider.comKiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis PigmentosaOctober 29, 2024 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingA Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesBy Gabriel Osorio-Mazilli | June 6, 2025View A Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesENTO, CTXR, CYCC, and KPRX Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$1.08 +0.17 (+18.34%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.12 +0.04 (+4.17%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Cyclacel Pharmaceuticals NASDAQ:CYCC$0.34 +0.00 (+1.01%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.32%) As of 06/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Entero Therapeutics NASDAQ:ENTO$0.53 +0.05 (+9.64%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.56 +0.03 (+5.46%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Kiora Pharmaceuticals NASDAQ:KPRX$3.20 +0.18 (+5.96%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.11 -0.09 (-2.81%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
